TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.110
+0.020 (1.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1.6 | 1.3 | 69.96 | 2.57 | 64.87 | 49.65 | Upgrade
|
| Revenue Growth (YoY) | -97.70% | -98.14% | 2619.12% | -96.03% | 30.67% | 208.38% | Upgrade
|
| Cost of Revenue | - | - | 1.4 | 1.4 | 15.98 | 6.34 | Upgrade
|
| Gross Profit | 1.6 | 1.3 | 68.57 | 1.17 | 48.9 | 43.31 | Upgrade
|
| Selling, General & Admin | 5.34 | 8.9 | 56.71 | 72.75 | 192.87 | 174.65 | Upgrade
|
| Research & Development | - | - | - | - | 10.43 | 19.79 | Upgrade
|
| Operating Expenses | 6.39 | 9.83 | 57.9 | 72.75 | 203.31 | 194.44 | Upgrade
|
| Operating Income | -4.79 | -8.52 | 10.66 | -71.58 | -154.41 | -151.13 | Upgrade
|
| Interest Expense | - | - | - | - | -28.58 | -17.38 | Upgrade
|
| Interest & Investment Income | 0.11 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.94 | 0.78 | -0.12 | 0.27 | 0.6 | 2.5 | Upgrade
|
| EBT Excluding Unusual Items | -2.75 | -7.74 | 10.55 | -71.31 | -182.39 | -166.01 | Upgrade
|
| Merger & Restructuring Charges | - | - | -9.47 | - | - | - | Upgrade
|
| Asset Writedown | -1.26 | - | - | - | -1.13 | -0.08 | Upgrade
|
| Other Unusual Items | - | - | - | -8 | - | -10.06 | Upgrade
|
| Pretax Income | -4.01 | -7.74 | 1.07 | -79.31 | -183.52 | -176.15 | Upgrade
|
| Income Tax Expense | -0.04 | -0.04 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -3.97 | -7.7 | 1.07 | -79.31 | -183.52 | -176.15 | Upgrade
|
| Earnings From Discontinued Operations | 0.65 | -2.58 | 110.92 | -93.11 | - | - | Upgrade
|
| Net Income | -3.32 | -10.28 | 112 | -172.42 | -183.52 | -176.15 | Upgrade
|
| Net Income to Common | -3.32 | -10.28 | 112 | -172.42 | -183.52 | -176.15 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 10 | 9 | 8 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 10 | 9 | 8 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 9.82% | 11.48% | 17.66% | 44.39% | 11.89% | 9.48% | Upgrade
|
| EPS (Basic) | -0.29 | -0.98 | 12.41 | -21.66 | -33.29 | -35.75 | Upgrade
|
| EPS (Diluted) | -0.29 | -0.99 | 11.95 | -21.66 | -33.50 | -36.00 | Upgrade
|
| Free Cash Flow | -7.12 | -48.14 | -4.08 | -142.73 | -159.68 | -168.17 | Upgrade
|
| Free Cash Flow Per Share | -0.62 | -4.61 | -0.44 | -17.93 | -28.96 | -34.13 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 98.00% | 45.51% | 75.37% | 87.24% | Upgrade
|
| Operating Margin | -300.19% | -654.61% | 15.24% | -2781.85% | -238.02% | -304.40% | Upgrade
|
| Profit Margin | -207.77% | -789.40% | 160.08% | -6700.93% | -282.90% | -354.79% | Upgrade
|
| Free Cash Flow Margin | -446.18% | -3697.47% | -5.83% | -5547.10% | -246.14% | -338.73% | Upgrade
|
| EBITDA | -4.55 | -8.4 | 11.86 | -70.84 | -150.34 | -149.73 | Upgrade
|
| EBITDA Margin | -284.77% | - | 16.95% | - | -231.75% | - | Upgrade
|
| D&A For EBITDA | 0.25 | 0.12 | 1.19 | 0.74 | 4.07 | 1.39 | Upgrade
|
| EBIT | -4.79 | -8.52 | 10.66 | -71.58 | -154.41 | -151.13 | Upgrade
|
| EBIT Margin | - | - | 15.24% | - | -238.02% | - | Upgrade
|
| Revenue as Reported | 1.3 | 1.3 | 69.96 | 2.57 | 64.87 | 49.65 | Upgrade
|
| Advertising Expenses | - | - | - | - | 35.8 | 9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.